title: A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.
abstract: The objective of the present study was to systematically review the clinical and economic outcomes of olmesartan as monotherapy or in combination with other antihypertensive agents in the treatment of hypertension. A literature search was performed using PubMed and the Cochrane library until December 2015, with no limit on publication date. Eligible studies were selected using predetermined inclusion and exclusion criteria, limiting articles to those published in the English language. Background information of the study, participants' characteristics and study outcomes were collected. Meta-analysis of data was not performed. Fifty-five studies were included, of which fifty investigated the clinical efficacy of olmesartan and five the cost-effectiveness of olmesartan. In general results from clinical trials evaluating the efficacy of olmesartan as monotherapy and as combination therapy demonstrated that olmesartan provided better antihypertensive blood pressure-lowering efficacy and was generally well tolerated compared with other antihypertensive agents. Results from economic evaluations indicated that olmesartan may be more cost-effective than other ARBs such as losartan, valsartan, irbesartan and candesartan, having the potential of decreasing the overall medical costs of care for patients with hypertension. Evidence from the present systematic review confirms the antihypertensive efficacy and good safety profile of olmesartan both as monotherapy and as combination therapy. Olmesartan was also found to be cost-effective compared with other ARBs, though this area has yet relatively poor evidence and needs to further be explored.
authors.affiliation: EVROSTON LP, Chatzigianni Mexi 5, 115 28 Athens, Greece; Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Company, Chatzigianni Mexi 5, 115 28 Athens, Greece. Electronic address: g.kourlaba@evroston.com.
authors.forename: G
authors.initials: G
authors.lastname: Kourlaba
authors.affiliation: EVROSTON LP, Chatzigianni Mexi 5, 115 28 Athens, Greece.
authors.forename: F
authors.initials: F
authors.lastname: Gialama
authors.affiliation: 1st Depertment of Cardiology, University of Athens, Hippocration Hospital, Vassilisis Sophias 114, 115 27, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Tsioufis
authors.affiliation: Department of Health Services Organization, National School of Public Health, 196 Alexandras Avenue, 115 21 Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Maniadakis
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000191:economics / Q000494:pharmacology; D003362:Cost-Benefit Analysis; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000191:economics; D007093:Imidazoles / Q000191:economics / Q000494:pharmacology; D013777:Tetrazoles / Q000191:economics / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan
keywords: Economic evaluation; Efficacy; Hypertension; Olmesartan; Review; Safety